Challenges in musculoskeletal pain treatment: focus on nimesulide
At present time effective pain relief is one of the most important problems of contemporary society. Overwhelming majority of the diseases is accompanied by pain and the prevalence rate of pain syndrome of different etiology is substantially increasing in elderly patients. The primary disorders acco...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ZAO "Consilium Medicum"
2019-02-01
|
| Series: | Consilium Medicum |
| Subjects: | |
| Online Access: | http://consilium.orscience.ru/en/archive/2019/vol-21-2-2019/challenges-in-musculoskeletal-pain-treatment-focus-on-nimesulide_5400/?element |
| Summary: | At present time effective pain relief is one of the most important problems of contemporary society. Overwhelming majority of the diseases is accompanied by pain and the prevalence rate of pain syndrome of different etiology is substantially increasing in elderly patients. The primary disorders accompanied by musculoskeletal pain (MSP) are nonspecific low-back pain, osteoarthritis, and rheumatologic disorders of periarticular soft tissue such as tenosynovitis, tendinitis, and bursitis of various localizations. Because inflammation is the main mechanism of acute and chronic pain development, non-steroidal anti-inflammatory drugs (NSAIDs) should be considered the first line therapy for MSP treatment. For effective treatment of patients with MSP a medication fr om NSAIDs group with significant therapeutic action, rapid effect development and good safety profile should be chosen. Nimesulide (Nimesil®) has all of these qualities. Nimesulide is presented on pharmaceutical market in 15 European countries and has been successfully used by both foreign and Russian medical professionals for more than 30 years. The article discusses results of Russian and foreign studies wh ere nimesulide (Nimesil®) was demonstrated to be effective as pain-relieving and anti-inflammatory agent in treatment of many disorders accompanied by MSP. Its undoubtful advantages include rapidity of the onset of action, short period of half-life that excludes accumulation and related adverse effects, and better safety in comparison with traditional non-selective NSAIDs in terms of gastrointestinal tract complications development, and also wide experience of use including long-term use. |
|---|---|
| ISSN: | 2075-1753 2542-2170 |